Evidence map›Paper›PMID 38667336›Full record

ArticleCells2024

High Level of CD8

Paulina Kwaśnik, Joanna Zaleska, Dorota Link-Lenczowska, Magdalena Zawada, Hubert Wysogląd, Bogdan Ochrem, Grażyna Bober, Ewa Wasilewska, Iwona Hus, Monika Szarejko and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Paulina KwaśnikDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0002-4244-1213
Joanna ZaleskaDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0002-4417-7831
Dorota Link-LenczowskaDepartment of Hematology Diagnostics, Jagiellonian University Hospital in Kraków, 30-688 Kraków, Poland.
Magdalena ZawadaDepartment of Hematology Diagnostics, Jagiellonian University Hospital in Kraków, 30-688 Kraków, Poland.ORCID 0000-0001-9105-1767
Hubert WysoglądDepartment of Hematology, Jagiellonian University Hospital in Kraków, 30-688 Kraków, Poland.
Bogdan OchremDepartment of Hematology, Jagiellonian University Hospital in Kraków, 30-688 Kraków, Poland.
Grażyna BoberDepartment of Hematooncology and Bone Marrow Transplantation, School of Medicine in Katowice, Medical University of Silesia, 40-032 Katowice, Poland.
Ewa WasilewskaDepartment of Hematology, Medical University of Białystok, 15-276 Białystok, Poland.
Iwona HusDepartment of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
Monika SzarejkoDepartment of Hematology and Transplantology, Medical University of Gdańsk, 80-214 Gdańsk, Poland.
Witold PrejznerDepartment of Hematology and Transplantology, Medical University of Gdańsk, 80-214 Gdańsk, Poland.
Olga Grzybowska-IzydorczykDepartment of Hematology, Medical University of Łódź, 93-513 Łódź, Poland.
Agnieszka Klonowska-SzymczykDepartment of Hematology, Medical University of Łódź, 93-513 Łódź, Poland.
Ewa MędraśDepartment of Hematology, Neoplastic Blood Disorders and Bone Marrow Transplantation in Wrocław, 50-367 Wrocław, Poland.
Michał KiełbusDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0001-6156-6217
Tomasz SachaChair of Hematology, Jagiellonian University Medical College in Kraków, 31-501 Kraków, Poland.
Krzysztof GiannopoulosDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0003-0135-4030
Jagiellonian University · PLMedical University of Lublin · PLGdańsk Medical University · PLMedical University of Lodz · PLMedical University of Białystok · PLMedical University of Silesia · PL

Funding

National Science Center 2018/31/B/NZ6/03361
6 · The paper itself

Abstract

Treatment-free remission (TFR) is achieved in approximately half of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors. The mechanisms responsible for TFR maintenance remain elusive. This study aimed to identify immune markers responsible for the control of residual CML cells early in the TFR (at 3 months), which may be the key to achieving long-term TFR and relapse-free survival (RFS) after discontinuation of imatinib. Our study included 63 CML patients after imatinib discontinuation, in whom comprehensive analysis of changes in the immune system was performed by flow cytometry, and changes in the

Indexed as

CD8-Positive T-LymphocytesImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProgrammed Cell Death 1 ReceptorAdultAgedFemaleFusion Proteins, bcr-ablHumansMaleMiddle AgedYoung AdultFusion Proteins, bcr-ablImatinib MesylatePDCD1 protein, humanProgrammed Cell Death 1 Receptorchronic myeloid leukemia (CML)discontinuation of imatinibimmune biomarkertreatment-free remission (TFR)

Identifiers

PMID38667336
PMCPMC11048908
OpenAlexW4395012561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.